Columbus-based Visiox Pharmaceuticals has agreed to merge with Ocuvex Therapeutics, a New Hyde Park, N.Y.-based ophthalmic pharmaceutical company focused on developing and commercializing novel therapies for glaucoma and other disorders.
The strategic combination is intended to position the newly combined entity as an emerging leader in the eye care sector with an exciting portfolio of ophthalmic medicines.
Visiox's products will grow Ocuvex's market presence and accelerate the commercialization of its promising therapeutics. The company will operate under the Ocuvex name.
"The combination of Visiox and Ocuvex makes for a perfect match," Visiox CEO Ryan S. Bleekssaid in a statement. "We have reached significant milestones with our products and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care."
Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options.
